PharmAthene finds backers for research pact

PharmAthene has gained some powerful support in Washington for its plans to expand a herd of genetically modified goats used in drug research by housing the animals at a USDA facility in Maryland. One of the state's senators, Benjamin Cardin, has introduced a measure in the farm bill that would permit just that in a public-private partnership. PharmAthene has been developing Protexia--a therapy produced in goats' milk and used to protect people from nerve agents--under Project BioShield. PharmAthene is also in a race to produce a new anthrax vaccine, a field where Human Genome Sciences is widely considered the leader.

- read the report from The Washington Post

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.